Metastatic renal cell carcinoma treated with Peg-interferon alfa-2b

Acta Oncologica

Volumn 48, Issue 6, 2009, Pages 901-908

  Lyrdal, David ^a   Stierner, Ulrika ^a   Lundstam, Sven ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA2B; PROTEIN TYROSINE KINASE INHIBITOR; TAMOXIFEN; VASCULOTROPIN;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANOREXIA; ARTHRALGIA; ARTICLE; CANCER CONTROL; CANCER GROWTH; CANCER SURVIVAL; CHILL; CLINICAL ARTICLE; CONTROLLED STUDY; DIAPHORESIS; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEART ARRHYTHMIA; HUMAN; INTRAOCULAR HEMORRHAGE; KIDNEY CARCINOMA; KIDNEY FUNCTION; LUNG PARENCHYMA; MALE; MEDIASTINUM; METASTASIS; MOOD DISORDER; MYALGIA; NAUSEA; NEUROLOGIC DISEASE; PRIORITY JOURNAL; RIGOR; SIDE EFFECT; TREATMENT RESPONSE; VOMITING; WEIGHT REDUCTION;

AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; FEMALE; HUMANS; INTERFERON ALFA-2B; KIDNEY NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; POLYETHYLENE GLYCOLS; PROGNOSIS; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 70350642091     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.1080/02841860902795257     Document Type: Article

References (30)

1. Collaborators MRCRC. Interferon-alpha and survival in metastatic renal carcinoma: Early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators. Lancet 1999;353:14-7.
2. Quesada JR, Rios A, Swanson D, Trown P, Gutterman JU. Antitumor activity of recombinant-derived interferon alpha in metastatic renal cell carcinoma. J Clin Oncol 1985;/3:/ 1522-8.
3. Figlin RA, deKernion JB, Mukamel E, Palleroni AV, Itri LM, Sarna GP. Recombinant interferon alfa-2a in metastatic renal cell carcinoma: Assessment of antitumor activity and anti-interferon antibody formation. J Clin Oncol 1988;/6:/ 1604-10.
4. Wirth MP. Immunotherapy for metastatic renal cell carcinoma. Urol Clin North Am 1993;/20:/283-95.
5. Pyrhonen S, Salminen E, Ruutu M, Lehtonen T, Nurmi M, Tammela T, et al. Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol 1999;/17:/ 2859-67.
6. Bracarda S ECea. Sorafenib plus interferon alpha-2b in metastatic renal cell carcinoma: Results from RAPSODY (GOIRC Study 0681)-A randomized prospective Phase II Trial of two different treatment schedules. EAU 2008-23rd Annual EAU Congress 2008.
7. Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: A randomised, double-blind phase III trial. Lancet 2007;/370:/2103-11.
8. Glue P, Fang JW, Rouzier-Panis R, Raffanel C, Sabo R, Gupta SK, et al. Pegylated interferon-alpha2b: Pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group. Clin Pharmacol Ther 2000;/68:/556-67.
9. Wang YS, Youngster S, Grace M, Bausch J, Bordens R,Wyss DF. Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications. Adv Drug Deliv Rev 2002;/54:/ 70.
10. Motzer RJ, Rakhit A, Thompson J, Gurney H, Selby P, Figlin R, et al. Phase II trial of branched peginterferon-alpha 2a (40 kDa) for patients with advanced renal cell carcinoma. Ann Oncol 2002;/13:/1799-805.
11. Chang E, Boyd A, Nelson CC, Crowley D, Law T, Keough KM, et al. Successful treatment of infantile hemangiomas with interferon-alpha-2b. J Pediatr Hematol Oncol 1997;/19:/ 237-44.
12. Berg WJ, Divgi CR, Nanus DM, Motzer RJ. Novel investigative approaches for advanced renal cell carcinoma. Semin Oncol 2000;/27:/234-9.
13. Jacobsen J, Rasmuson T, Grankvist K, Ljungberg B. Vascular endothelial growth factor as prognostic factor in renal cell carcinoma. J Urol 2000;/163:/343-7.
14. Motzer RJ, Rakhit A, Ginsberg M, Rittweger K, Vuky J, Yu R, et al. Phase I trial of 40-kd branched pegylated interferon alfa-2a for patients with advanced renal cell carcinoma. J Clin Oncol 2001;/19:/1312-9. (Pubitemid 32202535)
15. Liu CH, Liang CC, Lin JW, Chen SI, Tsai HB, Chang CS, et al. Pegylated interferon alpha-2a versus standard interferon alpha-2a for treatment-naive dialysis patients with chronic hepatitis C: A randomised study. Gut 2008;/57:/ 525-30.
16. Michallet M, Maloisel F, Delain M, Hellmann A, Rosas A, Silver RT, et al. Pegylated recombinant interferon alpha-2b vs recombinant interferon alpha-2b for the initial treatment of chronic-phase chronic myelogenous leukemia: A phase III study. Leukemia 2004;/18:/309-15.
17. Bukowski R, Ernstoff MS, Gore ME, Nemunaitis JJ, Amato R, Gupta SK, et al. Pegylated interferon alfa-2b treatment for patients with solid tumors: A phase I/II study. J Clin Oncol 2002;/20:/3841-9.
18. Bex A, Mallo H, Kerst M, Haanen J, Horenblas S, de Gast GC. A phase-II study of pegylated interferon alfa-2b for patients with metastatic renal cell carcinoma and removal of the primary tumor. Cancer Immunol Immunother 2005;/54:/ 713-9.
19. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;/92:/205-16.
20. Gehan EA. The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent. J Chronic Dis 1961;/13:/346-53.
21. Glue P, Rouzier-Panis R, Raffanel C, Sabo R, Gupta SK, Salfi M, et al. A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. The Hepatitis C Intervention Therapy Group. Hepatology 2000;/32:/647-53.
22. Melichar B, Koralewski P, Ravaud A, Pluzanska A, Bracarda S, Szczylik C, et al. First-line bevacizumab combined with reduced dose interferon-{alpha}2a is active in patients with metastatic renal cell carcinoma. Ann Oncol 2008;/19:/1470-6.
23. Fossa S, Jones M, Johnson P, Joffe J, Holdener E, Elson P, et al. Interferon-alpha and survival in renal cell cancer. Br J Urol 1995;/76:/286-90.
24. Flanigan RC, Salmon SE, Blumenstein BA, Bearman SI, Roy V, McGrath PC, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 2001;/345:/ 1655-9.
25. Elson PJ, Witte RS, Trump DL. Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma. Cancer Res 1988;/48:/7310-3.
26. Fossa SD, Kramar A, Droz JP. Prognostic factors and survival in patients with metastatic renal cell carcinoma treated with chemotherapy or interferon-alpha. Eur J Cancer 1994;/30A:/1310-4.
27. Negrier S, Escudier B, Gomez F, Douillard JY, Ravaud A, Chevreau C, et al. Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: A report from the Groupe Francais d'Immunotherapie. Ann Oncol 2002;/13:/1460-8.
28. Alamdari FI, Rasmuson T, Grankvist K, Ljungberg B. Angiogenesis and other markers for prediction of survival in metastatic renal cell carcinoma. Scand J Urol Nephrol 2007;/41:/5-9.
29. Quesada JR, Talpaz M, Rios A, Kurzrock R, Gutterman JU. Clinical toxicity of interferons in cancer patients: A review. J Clin Oncol 1986;4:234-43.
30. Gupta SK, Pittenger AL, Swan SK, Marbury TC, Tobillo E, Batra V, et al. Single-dose pharmacokinetics and safety of pegylated interferon-a2b in patients with chronic renal dysfunction. J Clin Pharmacol 2002;42:1109-15.